24/7 Market News Snapshot 03 September, 2025 – Autonomix Medical, Inc. Common Stock (NASDAQ:AMIX)

September 3, 2025

DENVER, Colo., 03 September, 2025 (www.247marketnews.com) – (NASDAQ:AMIX) are discussed in this article.
Autonomix Medical, Inc. is experiencing significant momentum in its trading activity, with shares currently priced at $1.335, marking a robust 7.66% increase from the prior day’s closing price of $1.240. The stock opened at $1.30, indicating strong investor sentiment and potential bullish momentum in the market. With a trading volume of 1.27 million shares, there is noticeable interest and engagement among traders. This positive trend may hint at a potential breakout above key resistance levels, making it crucial for analysts to track support and resistance dynamics to evaluate future price movements.

In addition to the favorable trading environment, Autonomix is advancing its leadership in pain management solutions for patients diagnosed with severe pancreatic cancer. Recent results from a longer-term post hoc analysis of its first-in-human proof-of-concept study reveal a remarkable 65.6% reduction in pain levels among the patient cohort. Specifically, the mean pain score decreased significantly from 7.75 to 2.67 on the Visual Analog Scale (VAS) after three months, with all responders successfully eliminating opioid use.

These compelling findings underscore significant improvements in patient quality of life, including enhanced sleep quality, increased energy, and greater daily activity engagement, coupled with reductions in symptoms such as tension and nausea. CEO Brad Hauser highlighted the implications of these results, noting that they extend upon previous positive outcomes and signify the potential for transformative changes in oncology treatment paradigms.

Looking ahead, Autonomix plans to progress to a second proof-of-concept phase, expanding its research to target additional visceral cancer types. This strategic initiative reflects the company’s commitment to revolutionizing pain management across medical disciplines and ongoing dedication to improving patient outcomes. The advancements position Autonomix as a frontrunner in innovative cancer pain treatment methodologies.

Related news for (AMIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.